ADVFN US – Market Content Editor
-
Wall Street Set for Higher Open as Progress in U.S.-Iran Talks Boosts Sentiment: Dow Jones, S&P, Nasdaq
U.S. stock futures pointed to a modestly positive start on Monday, with investors encouraged by reports of progress in diplomatic negotiations between the United States and Iran and by a continued decline in oil prices. The positive tone follows strong gains recorded during the previous trading session, although investors remain cautious as they await further…
-
SpaceX’s Market Debut Ignites Investor Enthusiasm in First Week of Trading
SpaceX (NASDAQ:SPCX) delivered one of the most closely watched stock market debuts in recent history, with shares soaring during their first week of trading as investors rushed to gain exposure to Elon Musk’s space, connectivity and artificial intelligence business. Since pricing its initial public offering at $135 per share on June 12, the stock has…
-
Credo Technology Gains as Evercore Launches Coverage with $325 Price Target
Credo Technology Group (NASDAQ:CRDO) shares rose 3.5% on Monday after Evercore ISI initiated coverage of the semiconductor company with an Outperform rating and a $325 price target, highlighting what it sees as substantial upside from expanding opportunities in AI networking infrastructure. The target sits roughly 20% above Friday’s closing price of $271.83 and reflects Evercore’s…
-
Robinhood Shares Fall After Announcing $2 Billion Convertible Notes Offering (HOOD)
Robinhood Markets (NASDAQ:HOOD) shares declined 4% on Monday after the online brokerage revealed plans to raise $2.0 billion through a private placement of convertible senior notes due in 2029. The market reaction reflected investor concerns about the potential for future shareholder dilution, despite the company positioning the transaction as a move to strengthen its financial…
-
AbbVie Strikes $10.9 Billion Deal for Apogee to Strengthen Future Immunology Portfolio (ABBV)
AbbVie (NYSE:ABBV) announced on Monday that it has agreed to acquire Apogee Therapeutics (NASDAQ:APGE) for $10.9 billion, marking its largest acquisition in more than five years and reinforcing its commitment to expanding its next-generation immunology pipeline. The transaction ranks among the biggest biotechnology deals of 2026 and highlights continued consolidation across the pharmaceutical sector as…
-
Taysha Advances Rett Syndrome Programme as Pivotal Trial Enrollment Completes (TSHA)
Taysha Gene Therapies Inc (NASDAQ:TSHA) shares rose 3.6% in premarket trading on Monday after the company announced the completion of patient dosing in its pivotal Rett syndrome study and released updated long-term clinical data for its lead gene therapy candidate, TSHA-102. The biotechnology company said the latest results continue to support the therapy’s safety profile…
-
Amazon Prime Day Set to Generate Record Online Spending as Retailers Compete for Shoppers (AMZN)
Amazon.com Inc. (NASDAQ:AMZN) is preparing to launch its 12th annual Prime Day event on Tuesday, with industry forecasts pointing to a significant surge in online spending across the retail sector. According to Adobe Inc., the four-day promotion is expected to drive approximately $26.3 billion in online sales across Amazon and rival retailers, representing a 9%…
-
Nuvectis Expands Pipeline with Haisco Licensing Agreement for Two Clinical-Stage Drug Candidates (NVCT)
Nuvectis Pharma Inc (NASDAQ:NVCT) shares gained 5.7% in premarket trading on Monday after the company announced a licensing agreement with Haisco Pharmaceutical Group that grants it exclusive rights outside China to two late-stage clinical assets. The transaction significantly broadens Nuvectis’ development portfolio, adding programmes in complement-mediated diseases and strengthening its oncology pipeline. Deal Adds NXP100…
-
BitFuFu Shares Climb After Launching $5 Million Share Repurchase Plan
BitFuFu Inc (NASDAQ:FUFU) shares rose 8.2% in premarket trading on Monday after the Bitcoin mining company unveiled a new share buyback programme aimed at returning capital to shareholders. The initiative signals management’s confidence in the company’s long-term outlook while providing additional flexibility to deploy capital during periods of market volatility. Board Approves Two-Year Repurchase Programme…
-
Palvella Shares Advance After FDA Grants Rolling Review for Rare Disease Therapy
Palvella Therapeutics Inc (NASDAQ:PVLA) shares gained 5% in premarket trading on Monday after the company announced that the U.S. Food and Drug Administration had granted rolling review status to its New Drug Application (NDA) for QTORIN rapamycin, a treatment for microcystic lymphatic malformations. The regulatory development marks another step forward in the company’s efforts to…